Molecular diagnostic tests are the essential tools needed to closely match a more careful diagnosis at an early stage with new drugs that are designed to precisely target disease in carefully identified patient groups. That kind of personalized medicine is expected to greatly increase the response rate that patients have to a drug, which today is often a hit-and-miss approach, and advance the response time to treating disease. And Nanosphere just raised $57 million from investors who believe that the company's use of nanotechnology in the ultra-sensitive pursuit of molecular materials can offer a big improvement over the current generation of diagnostic tools on the market. Small Times (http://www.smalltimes.com/document_display.cfm?document_id=11560)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Motus GI’s Pure-Vu System Receives Chinese Patent
The device previously received 510(k) clearance from the FDA and CE Mark approval in Europe.
House Committee Approves Spending Bill to Raise FDA’s Budget
The Senate is expected to mark up its version of the bill this week.